Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
? Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ? ? 7 of 12 patients (58%) achieved absolute HbF levels =20%; all patients achieved at least a 6.5% absolute increase in HbF ? ? Improvements in markers of hemolysis, improved erythropoiesis, and a 1 g/dL increase in total hemoglobin ? ? 7 of 12 patients (58%) reported zero VOCs during the treatment period ? ? Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ? ? Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ? ? Conference call and webcast scheduled for 8:00 a.m. ET today ? CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developi
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.MarketBeat
- Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025GlobeNewswire
FULC
Earnings
- 2/24/26 - In-Line
FULC
Sec Filings
- 2/24/26 - Form S-8
- 2/24/26 - Form 10-K
- 2/24/26 - Form 8-K
- FULC's page on the SEC website